FDA Needs Ongoing, Public Approach to Risk-Benefit Assessments: IOM
The FDA needs to take an ongoing, lifecycle approach to assessing the risk-benefit profiles of new drugs and should seek more public input during the process, a new Institute of Medicine (IOM) report urges.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.